Table 1 Clinicopathological and treatment characteristics of the patients enrolled in the study
Clinicopathological characteristics | MRD-positive (%) | MRD-negative (%) |
|---|---|---|
Age at diagnosis | ||
50–60 | 1 (33.33) | 4 (23.52) |
> 60 | 2 (66.66) | 13 (76.47) |
Tumor type | ||
IDC | 2 (66.66) | 13 (76.47) |
ILC | 1 (33.33) | 3 (17.64) |
Other | 0 (0) | 1 (5.88) |
Tumor size | ||
T1 | 1 (33.33) | 1 (5.88) |
T2 | 1 (33.33) | 13 (76.47) |
T3 | 1 (33.33) | 2 (11.76) |
T4 | 0 (0) | 1 (5.88) |
Lymph nodes | ||
N0 | 0 (0) | 1 (5.88) |
N1 | 0 (0) | 2 (11.76) |
N2 | 1 (33.33) | 9 (52.94) |
N3 | 2 (66.66) | 5 (29.41) |
Surgery | ||
Breast conserving | 2 (66.66) | 11 (64.70) |
Mastectomy | 1 (33.33) | 5 (29.41) |
Bilateral mastectomy | 0 (0) | 1 (5.88) |
Adjuvant Radiation | ||
Y | 3 (100) | 17 (100) |
N | 0 (0) | 0 (0) |
Chemotherapy | ||
Y | 3 (100) | 15 (88.23) |
N | 0 (0) | 2 (11.76) |
Adjuvant Endocrine Therapy | ||
Y | 3 (100) | 17 (100) |
N | 0 (0) | 0 (0) |
Type of Endocrine Therapy | ||
TAM | 0 (0) | 0 (0) |
AI | 3 (100) | 12 (70.58) |
TAM + AI | 0 (0) | 5 (29.41) |
Time in endocrine therapy | ||
> 5 years and ongoing | 0 (0) | 2 (11.76) |
< 5 years and ongoing | 0 (0) | 0 (0) |
> 5 years and completed | 3 (100) | 15 (88.23) |
< 5 years and completed | 0 (0) | 0 (0) |
Treated with CDK4/6 inhibitors | ||
Y | 0 (0) | 0 (0) |
N | 3 (100) | 17 (100) |